Edgewise Therapeutics, Inc. (EWTX) Current Ratio
- Current ratio · latest quarter: Value 16.24×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 16.24× | Current assets / current liabilities. $471.52M ÷ $29.04M ≈ 16.24× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 471.52M USD | Assets, Current |
| Current obligations | 29.04M USD | Liabilities, Current |
| Cash and equivalents | 72.32M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 4.67M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $471.52M | $29.04M | $72.32M | (m) | (m) | (m) | $4.67M | (m) | 16.24× |
| 2026-03-31 | $509.79M | $22.54M | $33.21M | (m) | (m) | (m) | $7.29M | (m) | 22.61× |
| 2025-12-31 | $543.38M | $27.37M | $61.15M | (m) | (m) | (m) | $6.01M | (m) | 19.85× |
| 2025-09-30 | $573.90M | $21.65M | $46.00M | (m) | (m) | (m) | $6.16M | (m) | 26.51× |
| 2025-06-30 | $603.25M | $20.90M | $43.40M | (m) | (m) | (m) | $8.32M | (m) | 28.87× |
| 2025-03-31 | $443.18M | $21.11M | $49.92M | (m) | (m) | (m) | $8.79M | (m) | 20.99× |
| 2024-12-31 | $475.48M | $23.86M | $41.67M | (m) | (m) | (m) | $5.58M | (m) | 19.93× |
| 2024-09-30 | $499.44M | $18.96M | $44.81M | (m) | (m) | (m) | $5.65M | (m) | 26.35× |
| 2024-06-30 | $519.44M | $17.18M | $43.48M | (m) | (m) | (m) | $6.80M | (m) | 30.24× |
| 2024-03-31 | $541.43M | $14.60M | $30.26M | (m) | (m) | (m) | $4.72M | (m) | 37.08× |
| 2023-12-31 | $327.00M | $16.77M | $86.10M | (m) | (m) | (m) | $4.03M | (m) | 19.50× |
| 2023-09-30 | $297.92M | $16.34M | $32.96M | (m) | (m) | (m) | $5.32M | (m) | 18.23× |
| 2023-06-30 | $317.00M | $14.40M | $31.81M | (m) | (m) | (m) | $3.78M | (m) | 22.01× |
| 2023-03-31 | $333.36M | $12.71M | $48.23M | (m) | (m) | (m) | $3.88M | (m) | 26.22× |
| 2022-12-31 | $357.00M | $16.59M | $21.99M | (m) | (m) | (m) | $6.11M | (m) | 21.53× |
| 2022-09-30 | $370.14M | $13.30M | $109.75M | (m) | (m) | (m) | $5.76M | (m) | 27.82× |
| 2022-06-30 | $253.34M | $9.22M | $18.34M | (m) | (m) | (m) | $2.83M | (m) | 27.49× |
| 2022-03-31 | $268.62M | $10.00M | $34.45M | (m) | (m) | (m) | $5.34M | (m) | 26.85× |
| 2021-12-31 | $283.77M | $10.52M | $15.57M | (m) | (m) | (m) | $3.84M | (m) | 26.97× |
| 2021-09-30 | $293.24M | $8.75M | $10.57M | (m) | (m) | (m) | $2.29M | (m) | 33.50× |
| 2021-06-30 | $302.97M | $6.74M | $50.40M | (m) | (m) | (m) | $2.82M | (m) | 44.96× |
| 2021-03-31 | $310.55M | $4.85M | $221.04M | (m) | (m) | (m) | $1.62M | (m) | 64.02× |
| 2020-12-31 | $129.65M | $4.34M | $104.92M | (m) | (m) | (m) | $1.58M | (m) | 29.86× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |